Theodore Gourdin to Male
This is a "connection" page, showing publications Theodore Gourdin has written about Male.
Connection Strength
0.299
-
Recent advances in the treatment of advanced prostate cancer: maximizing existing therapies while searching for novel solutions. Curr Opin Oncol. 2022 05 01; 34(3):228-233.
Score: 0.043
-
Highlighting recent treatment advances in metastatic prostate cancer: expanding the treatment arsenal. Curr Opin Oncol. 2021 05 01; 33(3):252-256.
Score: 0.040
-
Recent progress in treating advanced prostate cancer. Curr Opin Oncol. 2020 05; 32(3):210-215.
Score: 0.038
-
Optimization of therapies for men with advanced prostate cancer: a review of recent developments with a look toward the future. Curr Opin Oncol. 2019 05; 31(3):188-193.
Score: 0.035
-
Recent advances in the management of metastatic prostate cancer: optimizing use of existing therapies, while searching for novel interventions. Curr Opin Oncol. 2018 05; 30(3):159-164.
Score: 0.033
-
Utility of cell-free nucleic acid and circulating tumor cell analyses in prostate cancer. Asian J Androl. 2018 May-Jun; 20(3):230-237.
Score: 0.033
-
High frequency of rare structural chromosome abnormalities at relapse of cytogenetically normal acute myeloid leukemia with FLT3 internal tandem duplication. Cancer Genet. 2014 Oct-Dec; 207(10-12):467-73.
Score: 0.025
-
Elevated serum CEA is associated with liver metastasis and distinctive circulating tumor DNA alterations in patients with castration-resistant prostate cancer. Prostate. 2022 09; 82(13):1264-1272.
Score: 0.011
-
Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis. J Immunother Cancer. 2020 10; 8(2).
Score: 0.010
-
Cabozantinib use in metastatic renal cell carcinoma patients in clinical practice: Evaluation of dosing patterns, tolerability, and outcomes compared to clinical trials. J Oncol Pharm Pract. 2020 Jun; 26(4):861-865.
Score: 0.009
-
Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer. Cancer. 2019 05 01; 125(9):1459-1469.
Score: 0.009
-
Immune-related adverse events are linked with improved progression-free survival in patients receiving anti-PD-1/PD-L1 therapy. Semin Oncol. 2018 06; 45(3):156-163.
Score: 0.008
-
Ten-day decitabine as initial therapy for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy. Leuk Lymphoma. 2014 Jul; 55(7):1533-7.
Score: 0.006